
This copy is for your personal, non-commercial use only.

If you wish to distribute this article to others, you can order high-quality copies for your colleagues, clients, or customers by [clicking here](#).

Permission to republish or repurpose articles or portions of articles can be obtained by following the guidelines [here](#).

The following resources related to this article are available online at www.sciencemag.org (this information is current as of January 13, 2011):

Updated information and services, including high-resolution figures, can be found in the online version of this article at:

<http://www.sciencemag.org/content/296/5566/356.full.html>

Supporting Online Material can be found at:

<http://www.sciencemag.org/content/suppl/2002/05/15/1068284.DC1.html>

A list of selected additional articles on the Science Web sites **related to this article** can be found at:

<http://www.sciencemag.org/content/296/5566/356.full.html#related>

This article **cites 19 articles**, 12 of which can be accessed free:

<http://www.sciencemag.org/content/296/5566/356.full.html#ref-list-1>

This article has been **cited by** 198 article(s) on the ISI Web of Science

This article has been **cited by** 85 articles hosted by HighWire Press; see:

<http://www.sciencemag.org/content/296/5566/356.full.html#related-urls>

This article appears in the following **subject collections**:

Virology

<http://www.sciencemag.org/cgi/collection/virology>

$\alpha\beta$ subunit interfaces are extensive, include the P cluster in both $\Delta nifB$ -Av1 and Av1, and should remain intact. However, the rearrangement of the α III domain, in addition to generating the opening for FeMoco insertion, may also create a potential interaction domain that enables residues found in the disordered region of the $\Delta nifB$ -Av1 structure to dock with the FeMoco donor.

References and Notes

1. R. M. Allen, R. Chatterjee, M. S. Madden, P. W. Ludden, V. K. Shah, *Crit. Rev. Biotechnol.* **14**, 225 (1994).
2. B. K. Burgess, D. J. Lowe, *Chem. Rev.* **96**, 2983 (1996).
3. J. B. Howard, D. C. Rees, *Chem. Rev.* **96**, 2965 (1996).
4. B. E. Smith, *Adv. Inorg. Chem.* **47**, 159 (1999).
5. D. C. Rees, J. B. Howard, *Curr. Opin. Chem. Biol.* **4**, 559 (2000).
6. B. Schmid, H.-J. Chiu, V. Ramakrishnan, J. B. Howard, D. C. Rees, in *Handbook of Metalloproteins*, A. Messerschmidt, R. Huber, K. Wieghardt, T. L. Poulos, Eds. (Wiley, Chichester, UK, 2001), vol. 2, pp. 1025–1036.
7. J. Christiansen, D. R. Dean, L. C. Seefeldt, *Annu. Rev. Plant Physiol. Plant Mol. Biol.* **52**, 269 (2001).
8. J. Kim, D. C. Rees, *Nature* **360**, 553 (1992).
9. V. K. Shah, W. J. Brill, *Proc. Natl. Acad. Sci. U.S.A.* **74**, 3249 (1977).
10. The His-tag version of the *A. vinelandii* MoFe protein from a $\Delta nifB$ strain (DJ1143) contains eight His located between residues α 3 and α 4. Because an identically His-tagged version of an otherwise wild-type MoFe protein has full in vivo and in vitro activities, structural features that are critical for FeMoco insertion are not affected by this His-tag extension (17).
11. J. Christiansen, P. J. Goodwin, W. N. Lanzilotta, L. C. Seefeldt, D. R. Dean, *Biochemistry* **37**, 12611 (1998).
12. J. W. Peters et al., *Biochemistry* **36**, 1181 (1997).
13. S. M. Mayer, D. M. Lawson, C. A. Gormal, S. M. Roe, B. E. Smith, *J. Mol. Biol.* **292**, 871 (1999).
14. A movie showing schematically the rearrangements in domain α III between the structures of $\Delta nifB$ -Av1 and Av1 is available as supplemental material on Science Online at www.sciencemag.org/cgi/content/full/296/5566/352/DC1.
15. J. Kim, D. Woo, D. C. Rees, *Biochemistry* **32**, 7104 (1993).
16. Sequence conservation is based on a comparison of known nitrogenase MoFe protein sequences (SWISS-PROT) with the program BLAST (24).
17. Isolated FeMoco is known to be anionic (25). In the resting state of Av1, the core charge on the metals in FeMoco is proposed to be +1 (26) or +3 (27), with an overall negative charge supplied by homocitrate, which has a charge of -4 if the hydroxyl group is deprotonated.
18. V. C. Culotta et al., *J. Biol. Chem.* **272**, 23469 (1997).
19. J. S. Valentine, E. B. Gralla, *Science* **278**, 817 (1997).
20. A. C. Rosenzweig, *Acc. Chem. Res.* **34**, 119 (2001).
21. A. L. Lamb, A. S. Torres, T. V. O'Halloran, A. C. Rosenzweig, *Nature Struct. Biol.* **8**, 751 (2001).
22. P. Rangaraj, C. Rüttimann-Johnson, V. K. Shah, P. W. Ludden, *J. Biol. Chem.* **276**, 15968 (2001).
23. K. E. Brigle, M. C. Weiss, W. E. Newton, D. R. Dean, *J. Bacteriol.* **169**, 1547 (1987).
24. S. F. Altschul, W. Gish, W. Miller, E. W. Myers, D. J. Lipman, *J. Mol. Biol.* **215**, 403 (1990).
25. B. K. Burgess, *Chem. Rev.* **90**, 1377 (1990).
26. H.-I. Lee, B. J. Hales, B. M. Hoffman, *J. Am. Chem. Soc.* **119**, 11395 (1997).
27. S. J. Yoo, H. C. Angove, V. Papaefthymiou, B. K. Burgess, E. Münck, *J. Am. Chem. Soc.* **122**, 4926 (2000).
28. Supplementary information on the methods used is available on Science Online [see (14) for URL].
29. P. J. Kraulis, *J. Appl. Crystallogr.* **24**, 946 (1991).
30. E. A. Merritt, D. J. Bacon, *Methods Enzymol.* **277**, 505 (1997).
31. G. J. Kleywegt, *Acta Crystallogr.* **D52**, 842 (1996).
32. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.

33. W. Kabsch, C. Sander, *Biopolymers* **22**, 2577 (1983).
34. M. F. Sanner, A. J. Olson, J.-C. Spehner, *Biopolymers* **38**, 305 (1996).
35. N. Guex, M. C. Peitsch, *Electrophoresis* **18**, 2714 (1997).
36. This work was supported by NIH (B.K.B. D.R.D., and D.C.R.) and by a Deutsche Forschungsgemeinschaft research fellowship (B.S.). The rotation camera facil-

ity at the Stanford Synchrotron Radiation Laboratory is supported by the U.S. Department of Energy and NIH. Coordinates have been deposited with the Protein Data Bank (accession code 1L5H). Dedicated to the memory of Barbara K. Burgess (1 January 1951 to 30 December 2001).

18 January 2002; accepted 12 March 2002

Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus

Olen Kew,^{1*} Victoria Morris-Glasgow,² Mauricio Landaverde,³ Cara Burns,¹ Jing Shaw,¹ Zacarías Garib,⁴ Jean André,⁵ Elizabeth Blackman,² C. Jason Freeman,¹ Jaume Jorba,¹ Roland Sutter,⁶ Gina Tambini,³ Linda Venczel,³ Cristina Pedreira,⁷ Fernando Laender,⁸ Hiroyuki Shimizu,⁹ Tetsuo Yoneyama,⁹ Tatsuo Miyamura,⁹ Harrie van der Avoort,¹⁰ M. Steven Oberste,¹ David Kilpatrick,¹ Stephen Cochi,⁶ Mark Pallansch,¹ and Ciro de Quadros³

An outbreak of paralytic poliomyelitis occurred in the Dominican Republic (13 confirmed cases) and Haiti (8 confirmed cases, including 2 fatal cases) during 2000–2001. All but one of the patients were either unvaccinated or incompletely vaccinated children, and cases occurred in communities with very low (7 to 40%) rates of coverage with oral poliovirus vaccine (OPV). The outbreak was associated with the circulation of a derivative of the type 1 OPV strain, probably originating from a single OPV dose given in 1998–1999. The vaccine-derived poliovirus associated with the outbreak had biological properties indistinguishable from those of wild poliovirus.

The last case of poliomyelitis in the Americas associated with circulating indigenous wild poliovirus was reported in Peru in 1991 (1). The last poliomyelitis cases in the Caribbean occurred on the island of Hispaniola, which is divided between the Dominican Republic

(where the last reported case was in 1985) and Haiti (where the last reported case was in 1989). Since 1992, investigation of nearly 20,000 cases of acute flaccid paralysis (AFP) throughout the Americas (2) has found only sporadic cases of vaccine-associated paralytic poliomyelitis (VAPP) (3). The only known wild poliovirus infections in the Americas after 1991 were associated with importations into Canada (4, 5). Neither of these importations was associated with paralytic disease, and there was no evidence of the spread of the virus to the wider community.

In the summer of 2000, cases of AFP were reported from Bonao, Dominican Republic (date of onset: 12 July), and Port-de-Paix, Haiti (date of onset: 28 August), communities that are separated by ~300 km (Fig. 1) (6). Stool specimens collected from the patients were positive for poliovirus type 1. An initial characterization of the isolates by nucleic acid probe hybridization (7) indicated that they were vaccine-derived poliovirus (VDPV). In countries using oral poliovirus vaccine (OPV), VDPV is occasionally isolated from the stools of patients with nonpolio AFP (2, 3). However, several observations raised concerns that the AFP cases in Hispaniola might be caused by

¹Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA 30333, USA. ²Caribbean Epidemiology Centre (CAREC) Laboratory, Pan American Health Organization (PAHO), 16-18 Jamaica Boulevard, Federation Park, Port-of-Spain, Trinidad and Tobago. ³Division of Vaccines and Immunization, PAHO, 525 Twenty-Third Street, N.W., Washington, DC 20037, USA. ⁴Ministry of Health, Avenida San Cristóbal esquina Tiradentes, Santo Domingo, Dominican Republic. ⁵Ministry of Public Health, Port-au-Prince, Haiti. ⁶Vaccine Preventable Disease Eradication Division, National Immunization Program, CDC, 1600 Clifton Road, Atlanta, GA 30333, USA. ⁷PAHO, Calle Pepillo Salcedo, Plaza de la Salud, Santo Domingo, Dominican Republic. ⁸PAHO, Number 295 Avenue John Brown, Port-au-Prince, Haiti. ⁹Department of Virology II, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo 162, Japan. ¹⁰Polio Laboratory, National Institute of Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3720 BA, Bilthoven, Netherlands.

*To whom correspondence should be addressed. E-mail: okew@cdc.gov

REPORTS

circulating wild poliovirus: (i) both patients had residual paralysis, (ii) the cases occurred during the peak season for enterovirus (and poliovirus) transmission, (iii) one patient was unimmunized and the other was incompletely immunized (had been given one OPV dose), and (iv) type 1 poliovirus is the primary agent of poliomyelitis outbreaks (8). A sequence characterization (6) of the two isolates, comparing the major capsid surface protein VP1, showed that they were unrelated [$<82\%$ VP1 sequence identity (6)] to wild type 1 polioviruses previously endemic to Hispaniola or elsewhere in the Americas or to any wild poliovirus currently found in other parts of the world (9) (Fig. 2). By contrast, the Haitian and Dominican isolates were closely related (97.4 and 98.1% VP1 sequence identity, respectively) to the Sabin type 1 OPV strain and to each other (98.0% VP1 sequence identity). However, the degree of VP1 sequence similarity to the OPV strain was substantially lower than is normally observed ($>99.5\%$) in isolates from cases of AFP or VAPP. Unlike the two cases in Hispaniola, cases of VAPP are rare (~ 1 case per 2 million doses of OPV distributed), sporadic, involve independent exposures to OPV, and are most frequently associated with poliovirus types 2 and 3 (10). Moreover, the sequence relationships between the two isolates (12 of the VP1 nucleotide substitutions distinguishing the isolates from Sabin 1 were shared between them) suggested that they were derived from a recent common ancestor, as is typical of wild polioviruses isolated during an outbreak (11, 12). Consequently, AFP surveillance was intensified to search for additional polio cases.

From 12 July 2000 to 31 July 2001, a total of 123 AFP cases were reported in the Dominican Republic, 13 of which have been confirmed as polio by isolation of poliovirus type 1 from either the patients or their healthy contacts (Fig. 1) (6). In Haiti, 33 AFP cases were investigated between 28 August 2000 and 31 July 2001. Seven additional cases associated with circulating type 1 VDPV were found in 2001 (Fig. 1). Two patients died of bulbar poliomyelitis. Only one patient had a record of receiving three doses of OPV. All others were unvaccinated (11 patients), incompletely vaccinated (7 patients), or had an unknown vaccination status (2 patients) (6).

Type 1 VDPV was isolated from 19 polio patients and 12 healthy contacts in the two countries (6). All 31 isolates were closely related to each other and appeared to be the progeny of a recent common OPV infection (Fig. 3). The VP1 nucleotide diversity (6) of the Haitian isolates (0.030 nucleotide differences per site) was substantially higher than that of the Dominican isolates (0.007 nucleotide differences per site). Isolates from the north of Haiti were more closely related to

each other than they were to the isolates from the south, which in turn represented three distinct lineages (Fig. 3).

The approximate times of key events in the transmission history of the outbreak virus can be estimated from the VP1 sequence relationships among isolates, the dates of specimen collection, and the rate of VP1 evolution (11). By assuming that the evolution rate within VP1 of the outbreak virus was 0.030 substitutions per synonymous site per year (6, 11), we estimated that the initiating OPV dose occurred in late 1998 or early 1999. We further estimated that the northern and southern lineages in Haiti diverged in

mid-1999 and that the southern lineages diverged again a few months later. The close sequence relationships among the Dominican isolates suggested that the common ancestral infection for this clade occurred in the spring of 2000.

All outbreak virus isolates were recombinants. The 5'-untranslated and capsid-region sequences were derived from Sabin 1, whereas most of the noncapsid sequences were derived from other species C enteroviruses (Fig. 4) (13). A block of recombinant sequences (positions 3811 to ~ 3952 ; 2A^{PRO}/2B region) was shared by all outbreak isolates. The close relationship (93.7 to 100% se-





Fig. 1. Temporal distribution of confirmed cases of paralytic poliomyelitis (black bars), polio-compatible acute flaccid paralysis (AFP) cases (gray bars), and other AFP cases (white bars) in the Dominican Republic (upper panel) and Haiti (lower panel) from 1 January 2000 to 31 July 2001. Confirmed cases had type 1 VDPV isolated from stool. Polio-compatible cases had residual paralysis at 60 days after onset but no isolation of type 1 VDPV. Arrows indicate the dates of NIDs. The dashed arrow shafts indicate suboptimal OPV coverage of the first two NIDs in Haiti; the row of smaller arrows symbolizes the May to July 2001 rolling immunization campaigns in Haiti.

Fig. 2. Unrooted neighbor-joining tree (6) summarizing VP1 (nucleotides 2480 to 3385) sequence relationships among the Sabin 1 OPV strain, the first isolates from the 2000 outbreak in the Dominican Republic (case DOR00-013) and Haiti (case HAI00-003), the last isolates of the wild type 1 polioviruses previously indigenous to the Dominican Republic (1985) and Haiti (1985), the last isolates of the other type 1 poliovirus genotypes previously indigenous to the Americas (dashed lines connect to extinct genotypes), and 21 wild type 1 poliovirus isolates from cases occurring in polio-endemic countries of Africa and Asia in 1999 and 2000.



REPORTS

quence identity) among sequences within this block provides strong evidence of their introduction by a single recombination event and confirms that the outbreak virus was derived from a single source infection. Noncapsid sequences of the 21 Dominican isolates were generally very similar, except for isolates from three contacts of a Navarrete case (DOR00-041) (Figs. 3 and 4) (6), which had 3D^{pol} region sequences derived from another enterovirus. Noncapsid sequence relationships among the 10 Haitian isolates were more complex. Seven southern isolates and the Pilate isolate had recombination breakpoints in common with the main Dominican group. However, the isolates from the Port-de-Paix case and the fatal Port-au-Prince case differed in their noncapsid sequences from

the other Haitian and Dominican isolates and from each other (Fig. 4). At least four different enteroviruses recombined with the type 1 VDPV during its circulation in Hispaniola.

The outbreak VDPV had recovered two of the most important biological properties of wild polioviruses: the capacity to cause severe paralytic disease in humans and the capacity for extensive person-to-person transmission. All 31 isolates had a G→A substitution at nucleotide 480 in the 5'-untranslated region. This substitution restored a 480A:525U base pair within a dual stem-loop secondary structural element of the internal ribosome entry site that controls the efficiency of translation of poliovirus RNA (14) and represents a reversion of an important determinant of the attenuated phenotype of the

Sabin 1 OPV strain (15–17). Other alleles that confer attenuation or temperature sensitivity to Sabin 1 (16) had either reverted (at positions 935, 2438, and 2795) or had been exchanged out by recombination (at positions 6143, 6203, 7071, and 7441) (6). The genetic properties of the outbreak isolates were consistent with their association with paralytic disease in humans and with other biological properties determined experimentally. The first two outbreak isolates were found to be highly neurovirulent for PVR-Tg21 transgenic mice expressing the human receptor for poliovirus (6), and unlike Sabin 1, could replicate to high titers in HeLa cells at 39.5°C (6). Amino acid substitutions in virion surface residues (6, 18) correlated with the “non-vaccinelike” antigenic properties of the VDPV isolates (19).

Circulation of VDPV occurred in an environment of low vaccine coverage throughout Haiti and in parts of the Dominican Republic. In Haiti, reported coverage rates for three doses of OPV (OPV3) for children <1 year of age were the lowest in the Americas, falling to around 30% nationwide from 1992 to 1997, and remaining below 60% by 2000. Nationwide OPV3 coverage rates were higher in the Dominican Republic (ranging from 72 to 84% from 1993 to 2000), but coverage was very low (20 to 30%) in the outbreak communities. No mass OPV immunization campaigns in the form of National Immunization Days (NIDs) had been conducted in either country within the last 5 years.

The gaps in vaccine coverage were accompanied by gaps in surveillance, especially in Haiti. Nonetheless, a reasonable reconstruction of the events leading to the outbreak can be inferred from the combined epidemiologic and virologic data. The outbreak probably began in Haiti, when a routine OPV dose was given to a child living in a community with low vaccine coverage. As VDPV excreted by the OPV recipient spread to nonimmune children in the community, variants may have been selected for increased neurovirulence (14, 20) and transmissibility potentials. The outbreak in the Dominican Republic began with the importation of virus from one of the Haitian VDPV lineages into a low-OPV coverage community.

Evidence of circulating VDPV has recently been found elsewhere. In the Philippines, circulating type 1 VDPV has been associated with three cases of AFP in 2001 (21). In Egypt, type 2 VDPV circulated for an estimated 10 years (from 1983 to 1993) and was associated with 32 reported cases (22). In these examples, as in Hispaniola, the critical risk factors were poor population immunity resulting from gaps in OPV coverage and the absence of indigenous circulation of the corresponding wild poliovirus serotype.

The finding that VDPV can, under suit-




Fig. 3. Maximum likelihood tree (6) of VP1 sequence relationships among the Sabin 1 OPV strain (root of tree) and 28 type 1 VDPV isolates from the 2000–2001 outbreak in the Dominican Republic and Haiti. The location of the case and date of onset of paralysis are shown for each isolate. The isolates from the fatal cases in Haiti (HAI01-007 and HAI01-009) are indicated by asterisks. Isolate pairs that had identical VP1 sequences (DOR00-041c2, DOR00-041c3; DOR00-042, DOR00-042c1; HAI01-008c1, HAI01-008c2) are represented only once on the tree.




Fig. 4. Location of recombination breakpoints of the four different recombinant classes found among Hispaniola VDPV isolates. In the schematic of the poliovirus genome, the single open reading frame is indicated by a rectangle, flanked by the 5'- and 3'-untranslated regions (UTR). In rectangles A to E, Sabin 1–derived sequences are indicated by white fill, and sequences derived from enteroviruses other than the Sabin OPV strains are indicated by shaded or hatched fills. The rectangles symbolize sequences of A, Sabin 1; B, DOR00-013; C, DOR00-041c1; D, HAI00-003; and E, HAI01-007 (6).

able conditions, circulate and cause cases of poliomyelitis has important implications for current and future strategies of the World Health Organization (WHO) initiative to eradicate polio worldwide (23). First, the eradication of wild poliovirus, now at an advanced stage (23), must be completed as soon as possible. At the same time, it is imperative that immunity gaps in nonendemic countries are prevented, especially in tropical developing countries where the risk for poliovirus circulation is highest (24). After certification of wild poliovirus eradication, a carefully planned strategy for the orderly cessation of OPV use worldwide should be implemented. Finally, sensitive global poliovirus surveillance must be maintained for the foreseeable future, and emergency stockpiles of poliovirus vaccine established, for use in the event of any recurrent poliovirus transmission from chronic poliovirus excretors (25), a breach in poliovirus containment (25), or circulating VDPV.

References and Notes

1. F. C. Robbins, C. A. de Quadros, *J. Infect. Dis.* **175** (suppl. 1), S281 (1997).
2. C. A. de Quadros et al., *J. Infect. Dis.* **175** (suppl. 1), S37 (1997).
3. J. K. Andrus, P. M. Strebel, C. A. de Quadros, J. M. Olive, *Bull. WHO* **73**, 33 (1995).
4. M. A. Drebot et al., *Appl. Environ. Microbiol.* **63**, 519 (1997).
5. Pan American Health Organization, *EPI Newsl.* **18**, 4 (1996).
6. Supplementary figures and details of experimental procedures are available on Science Online at www.sciencemag.org/cgi/content/full/1068284/DC1.
7. L. De et al., *J. Clin. Microbiol.* **33**, 562 (1995).
8. P. A. Patriarca, R. W. Sutter, P. M. Oostvogel, *J. Infect. Dis.* **175**, S165 (1997).
9. O. M. Kew, M. N. Mulders, G. Y. Lipskaya, E. E. da Silva, M. A. Pallansch, *Semin. Virol.* **6**, 401 (1995).
10. P. M. Strebel et al., *Clin. Infect. Dis.* **14**, 568 (1992).
11. H.-M. Liu et al., *J. Virol.* **74**, 11153 (2000).
12. L. M. Shulman et al., *J. Clin. Microbiol.* **38**, 945 (2000).
13. M. S. Oberste, K. Maher, D. R. Kilpatrick, M. A. Pallansch, *J. Virol.* **73**, 1941 (1999).
14. A. R. Muzychenko et al., *Virus Res.* **21**, 111 (1991).
15. N. Kawamura et al., *J. Virol.* **63**, 1302 (1989).
16. M. J. Bouchard, D. H. Lam, V. R. Racaniello, *J. Virol.* **69**, 4972 (1995).
17. M. Gromeier, B. Bossert, M. Arita, A. Nomoto, E. Wimmer, *J. Virol.* **73**, 958 (1999).
18. P. D. Minor, *Curr. Top. Microbiol. Immunol.* **161**, 121 (1990).
19. H. G. A. M. van der Voort et al., *J. Clin. Microbiol.* **33**, 2562 (1995).
20. P. D. Minor, G. Dunn, *J. Gen. Virol.* **69**, 1091 (1988).
21. Centers for Disease Control and Prevention, *Morb. Mortal. Wkly. Rep.* **50**, 874 (2001).
22. ———, *Morb. Mortal. Wkly. Rep.* **50**, 41 (2001).
23. WHO, *Wkly. Epidemiol. Rec.* **76**, 126 (2001); for updates see www.who.int/vaccines-polio.
24. N. Nathanson, J. R. Martin, *Am. J. Epidemiol.* **110**, 672 (1979).
25. D. J. Wood, R. W. Sutter, W. R. Dowdle, *Bull. WHO* **78**, 347 (2000).
26. We thank N. Dybdahl-Sissoko, N. Mishrik, D. Moore, M. Staples, and A. J. Williams for characterization of poliovirus isolates before sequencing; J. Kim and J. Golub for sequencing some of the wild poliovirus type 1 isolates; R. Campagnoli for performing growth-rate studies of poliovirus isolates; P. Chenoweth for assistance with the mapping of the confirmed polio cases; L. Anderson, V. Cáceres, W. Dowdle, H. Gary, C. Maher, and R. Sanders for

helpful discussions; two anonymous reviewers for their constructive comments; and the virologists from the WHO Global Polio Laboratory Network for contributing the wild poliovirus isolates used in our comparisons.

22 November 2001; accepted 6 February 2002
Published online 14 March 2002;
10.1126/science.1068284

Include this information when citing this paper.

Requirement for a Peptidoglycan Recognition Protein (PGRP) in Relish Activation and Antibacterial Immune Responses in *Drosophila*

Kwang-Min Choe,^{1,2} Thomas Werner,³ Svenja Stöven,³ Dan Hultmark,³ Kathryn V. Anderson^{1,2*}

Components of microbial cell walls are potent activators of innate immune responses in animals. For example, the mammalian TLR4 signaling pathway is activated by bacterial lipopolysaccharide and is required for resistance to infection by Gram-negative bacteria. Other components of microbial surfaces, such as peptidoglycan, are also potent activators of innate immune responses, but less is known about how those components activate host defense. Here we show that a peptidoglycan recognition protein, PGRP-LC, is absolutely required for the induction of antibacterial peptide genes in response to infection in *Drosophila* and acts by controlling activation of the NF- κ B family transcription factor Relish.

In response to infection, *Drosophila* activates the transcription of a battery of antimicrobial peptide genes in cells of the fat body (the insect analog of the liver). Two major branches of this humoral response have been identified; in mammals, these responses require NF- κ B transcription factors (1). One branch activates antifungal responses and requires the receptor Toll and the NF- κ B family transcription factor Dif (2–4). The second branch, which is primarily antibacterial, requires the NF- κ B protein Relish, an I κ B kinase (IKK), a caspase, a mitogen-activated protein kinase kinase kinase, and the death-domain protein Imd (5–11).

We have taken a genetic approach to identifying genes required for the antibacterial response (12, 13). One gene that is absolutely required for the induction of the antibacterial response is *ird7* (*immune response deficient 7*). Two mutations in *ird7* identified in an ethylmethane sulfonate (EMS) mutagenesis screen (12, 13) prevented the induction of three antibacterial peptide genes, *Diptericin*, *Cecropin*, and *Defensin*, after infection by

either Gram-negative or Gram-positive bacteria (Fig. 1, A and B). Three other antimicrobial peptide genes, *Attacin*, *Metchnikowin*, and *Drosomycin*, also failed to be induced to normal levels. The profile of antimicrobial gene expression observed in the *ird7* mutants was similar to that observed in *imd*, *DmIkk β /ird5*, and *Relish* mutants after bacterial infection, but was distinct from that of *Toll* and *Dif* mutants (Fig. 1A). This pattern suggests that *ird7* is an essential component of the same signaling pathway that requires *imd* and *Relish*, but is not required for the Toll-Dif pathway. Both *ird7* mutants are homozygous viable and fertile, and blood cells from *ird7* mutants can phagocytose bacteria (14); these findings suggest that *ird7* is required specifically for the humoral immune response.

The transcription factor Relish directly activates antibacterial target genes in *Drosophila*. Relish is a compound protein similar to mammalian p100 and p105 (the precursors of the p52 and p50 subunits of NF- κ B), with an NH₂-terminal Rel homology and a COOH-terminal ankyrin repeat domain similar to that of the NF- κ B inhibitor I κ B (15). In response to immune challenge, full-length Relish (REL-110) is endoproteolytically clipped to generate the NH₂-terminal REL-68 fragment, which translocates into the nucleus, and the COOH-terminal REL-49 ankyrin repeat fragment, which remains stable in the cytoplasm (16) (Fig. 1C). In contrast to wild-type animals, no processing of Relish was detected in *ird7* mutant larvae (Fig. 1C). The

¹Molecular Biology Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. ²Molecular and Cell Biology Program, Weill Graduate School of Medical Sciences, Cornell University, 445 East 69th Street, New York, NY 10021, USA. ³Umeå Centre for Molecular Pathogenesis, Umeå University, SE-901 87 Umeå, Sweden.

*To whom correspondence should be addressed. E-mail: k-anderson@ski.mskcc.org